Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, Giancarlo Bisagni, Grazia Arpino, Maria Giuseppa Sarobba, Ferdinando Riccardi, Antonio Russo, Lucia Del Mastro, Francesco Cognetti, Filippo Montemurro, Antonio Bernardo, Adriano Gravina, Francesco Nuzzo, Francesco Perrone

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)474-485
Number of pages12
JournalThe Lancet Oncology
Volume19
Issue number4
DOIs
Publication statusPublished - 2018

Cite this